Login
Companies $TWST
$103.50 -$1.54 (1.47%) After hours
Twist Bioscience Corp logo

Twist Bioscience Corp

twistbioscience.com

What Do They Do?

Sells next-generation sequencing sample-preparation tools to diagnostic and research organizations, and synthetic DNA products and antibody-discovery services to biotech, pharmaceutical and industrial customers.

How Do They Make Money?

Customers pay for synthetic genes, oligo pools, DNA libraries and NGS tools when products ship. Biopharma customers may pay upfront and at milestones, for development work as it progresses, and through license payments.

revenue
SegmentShareRevenue
Synthetic genes
Sold outright

30%
FY2022: 30%
Oligo pools
Sold outright
5.4%
FY2022: 6.1%
DNA libraries
Sold outright
3.0%
FY2022: 3.0%
Antibody discovery
Mix
6.2%
FY2022: 12%
NGS tools
Sold outright

55%
FY2022: 49%

Who Are Their Customers?

Research and commercial customers across life sciences, industry and agriculture buy synthetic biology products and NGS tools, including diagnostic organizations and hospitals. Product sales use direct sales, e-commerce and distributors; biopharma partners work with business-development and sales representatives.

Do Revenues Turn Into Profits?

No. It lost $77.7M in FY2025.

Operating income, FY2025
−36% of revenue
▲ +38% (Loss) vs FY2024 (−$220.8M, −71%)
Net income, FY2025
−21% of revenue
▲ +63% (Loss) vs FY2024 (−$208.7M, −67%)
Free cash flow, FY2025
−20% of revenue
▼ −9% (Loss) vs FY2024 (−$69.2M, −22%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jun 30, 2026
Revenue
▲ +23%
vs $96.1M in Q3 FY2025
Net income
▼ Turned to a loss
vs $20.4M in Q3 FY2025
NGS applications share of revenue vs 57.6% in Q3 FY2025
  • Nov 12, 2026 Company issued fiscal 2027 revenue guidance Fiscal 2027 revenue guidance was $550 million to $560 million.

Growing. Revenue grew 2.8x in 4 years, from $132.3M in FY2021 to $376.6M in FY2025, about 30% a year.

DNA data storage The earlier report described DNA data storage as an application under development and a market opportunity; the latest report says Twist sold the business to Atlas, moving it outside the company's operations.

Biopharma services The earlier report framed biological drug discovery as a portfolio expansion opportunity alongside DNA and NGS products; the latest report includes biopharma services for antibody discovery, optimization and development among current revenue sources.

Revenue over time
Synthetic genes Oligo pools DNA libraries Antibody discovery NGS tools
$500M$250M$0

Who Do They Compete With?

Competes with GenScript Biotech, Azenta Life Sciences, Integrated DNA Technologies, DNA 2.0, Thermo Fisher Scientific, Eurofins Genomics, OriGene Technologies, Elegen, Ansa Biotechnologies, Telesis Bio, Illumina, Roche Holding, New England Bioloabs, Watchmaker Genomics, Agilent Technologies, Curia Global, Genovac, FairJourney Biologics, IONTAS, and Adimab

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support